🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

In-depth Analysis of the Immune Responses in the Upper Respiratory Tract in Older Adults Infected or Colonized With Streptococcus Pneumoniae (Spn)

Recruitingn/aAges 60 Years - 85 YearsAllUniversity Hospital, Geneva
NCT06998251 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The NoseSpn-Elderly study aims at characterizing the immune response in the upper respiratory tract in adults aged 60 and over diagnosed with a pneumonia due to a Streptococcus pneumoniae (Spn) infection. The immune response during the acute phase of the infection and after recovery will be compared to the immune response of asymptomatic Spn carriers as well as to the immune response of patients diagnosed with a viral respiratory infection (flu or respiratory syncytial virus (RSV)). The primary objective of this observational study is to quantify the inflammatory response in the nasal cavity and to correlate it with bacterial/viral load and with clinical parameters. The study also aims to compare the inflammatory response measured in the nose to that measured in the blood. Participants will have two study visits including a blood draw, several nasal samplings (nasal lining fluid and na

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion criteria: * Aged 60-85 years * Able to provide informed consent either independently or by a legal representative * Group 1 (Spn pneumonia patients): clinical and/or radiological signs of pneumonia * Group 1 (Spn pneumonia patients): positive Spn urinary antigen and/or blood culture and/or positive sputum test. * Group 2 (viral respiratory infection patients): clinical signs of a respiratory infection * Group 2 (viral respiratory infection patients): positive test for influenza or RSV * Group 3 (asymptomatic Spn-carriers): healthy without clinical signs of infection and no lower respiratory symptoms within the last month. Exclusion criteria: * Immunosuppression, * Use of inhalation and/or nasal steroids the last month * Intubation or under invasive mechanical ventilation * Long-term antibiotic treatment prior to disease onset
💊

What it tests

  • Not listed
📍

Where

1 site
Geneva University Hospitals
Geneva, Switzerland
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy